- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02546076
Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars (KELOID)
Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
Skin injuries due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars.
The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars.
The main hypothesis is that ablative fractional laser without heat/coagulation is equivalent to laser with heat/coagulation in terms of scars volume reduction, while the secondary hypothesis is that ablative fractional laser without heat/coagulation is superior in terms of post-operative erythema and hypopigmentation reduction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background
Skin injuries, such as lacerations or abrasions, due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Multiple modalities for improving the clinical appearance of scars have been attempted with varying success, including corticosteroids, dermabrasion, surgical revision, chemical peeling, silicone gel application, pressure therapy, and radiation. Lasers such as the carbon dioxide (CO2), erbium: yttrium-aluminum-garnet (Er:YAG), and pulsed dye (PDL) lasers have all been used with differing success in the treatment of scars. The goal of all these treatments is to soften depressions and stimulate neocollagenesis in order to fill in the residual defects.
Ablative lasers used for skin resurfacing, such as the CO2 and Er:YAG laser, can reduce various scars, but significant adverse effects limit their use, and patient downtime can be extensive. Owing to these potential risks, nonablative lasers have been developed as a safe alternative to ablative laser resurfacing, and have been reported to be effective and safe for scars. However outcomes have remained unsatisfactory and require several treatments to achieve satisfactory efficacy.
Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars, and some authors have suggested that treatment with fractional lasers for various scars, such as postoperative, atrophic, and acne scars, has been demonstrated to safely improve the appearance of the scars. However, there is a lack of studies comparing coagulation modality of such lasers.
Objective
The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars.
Methods
This is a single center, investigator initiated, double blind, within-subject split-lesion design, equivalence randomized clinical study.
Consecutive patients, referring to Dermatology outpatient and fulfilling inclusion criteria, are included. Participants are then randomly assigned to get treatment with Er:YAG laser on half of scar section side by equally splitting the lesion area in two symmetric and uniform parts. One side will be treated with coagulation while the other one will be without. In case of multiple lesions per patient, only the largest and most uniform one is selected for the study purpose.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Given written informed consent
- Skin type I-IV
- Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type
- Willingness and ability to adhere study protocol
Exclusion Criteria
- History of adverse events related to ablative fractional laser therapy
- Ablative resurfacing within the last 6 months on the scar
- Oral retinoid, any immunosuppressive treatments in the last 6 months
- Pregnancy, lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Laser coagulation
Er:YAG laser treatment with coagulation modality
|
The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
|
Active Comparator: Laser w/o coagulation
Er:YAG laser treatment without coagulation modality
|
The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Any reduction from baseline of scars volume as assessed by image analysis
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Any reduction from baseline of scars volume as assessed by image analysis
Time Frame: 4, 8, 12, 16, 24 weeks
|
4, 8, 12, 16, 24 weeks
|
Any improvement of scars as assessed by physician according to an ordinal 6-points scale
Time Frame: 4, 8, 12, 16, 24 weeks
|
4, 8, 12, 16, 24 weeks
|
Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale
Time Frame: 16, 24 weeks
|
16, 24 weeks
|
Erythema index as assessed by image analysis
Time Frame: 4, 8, 12, 16, 24 weeks
|
4, 8, 12, 16, 24 weeks
|
Hypopigmentation as assessed by image analysis
Time Frame: 4, 8, 12, 16, 24 weeks
|
4, 8, 12, 16, 24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maurice Adatto, MD, Dep. of Dermatology, Inselspital University Hospital, Bern (Switzerland)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Keloid
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keloid
-
CHA UniversityCompletedHypertrophic or Keloid ScarsKorea, Republic of
-
Queen Mary University of LondonWithdrawn
-
SolitonEmergent Clinical Consulting, LLCCompleted
-
Sensus HealthcareUnknownKeloid ScarUnited States
-
Sensus HealthcareUnknown
-
University of UlmCompleted
-
NYU Langone HealthCompleted
-
Northwestern UniversityCompleted
-
Our Lady of the Lake HospitalLouisiana State University Health Sciences Center in New OrleansCompletedPost-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of KeloidsKeloid | Keloid Scar Following SurgeryUnited States
-
Next Science TMJacksonville Center For Clinical ResearchWithdrawnKeloid Scar Following SurgeryUnited States
Clinical Trials on Laser coagulation
-
University of CagliariUniversity of FoggiaCompletedOvarian EndometriomaItaly
-
Region SkaneSuspended
-
Leiden University Medical CenterRecruitingTwin Anemia Polycythemia SequenceUnited States, Italy, Netherlands, Spain, Sweden
-
Shen-Zhen City Maternity and Child Healthcare HospitalCompletedPolycystic Ovary Syndrome | Infertility | Anovulation
-
State Scientific Centre of Coloproctology, Russian...UnknownAnal FistulaRussian Federation
-
Federal University of São PauloCompletedRadiation Injuries | TelangiectasisBrazil
-
University of Colorado, DenverNo longer available
-
Triemli HospitalUniversity of ZurichCompletedCoagulation Disorder, BloodSwitzerland
-
University of PecsUnknownPerioperative/Postoperative Complications | Abdominal Aortic Aneurism | Abdominal Aortic Rupture | Surgical Blood Loss
-
Virginia Commonwealth UniversityHemoSonics LLCCompleted